anmelden
OMX Nordic 40
2.685,57
PKT
-21,68
PKT
-0,80
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Nordic 40-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 27.01.20 | Ericsson (Telefon L.M.Ericsson) (B) Conviction Buy | Goldman Sachs Group Inc. | |
| 27.01.20 | Ericsson (Telefon L.M.Ericsson) (B) kaufen | Credit Suisse Group | |
| 27.01.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 27.01.20 | Ericsson (Telefon L.M.Ericsson) (B) buy | Kepler Cheuvreux | |
| 23.01.20 | AstraZeneca Sell | Goldman Sachs Group Inc. | |
| 22.01.20 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 22.01.20 | AstraZeneca Hold | Jefferies & Company Inc. | |
| 20.01.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 20.01.20 | ABB (Asea Brown Boveri) Hold | Deutsche Bank AG | |
| 17.01.20 | Novo Nordisk overweight | Barclays Capital | |
| 17.01.20 | Novo Nordisk Neutral | UBS AG | |
| 17.01.20 | ABB (Asea Brown Boveri) Sector Perform | RBC Capital Markets | |
| 17.01.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 16.01.20 | Volvo (B) Sell | UBS AG | |
| 16.01.20 | ABB (Asea Brown Boveri) buy | UBS AG | |
| 16.01.20 | Nokia buy | UBS AG | |
| 16.01.20 | Novo Nordisk overweight | Barclays Capital | |
| 16.01.20 | AstraZeneca overweight | Barclays Capital | |
| 16.01.20 | Novo Nordisk Outperform | Credit Suisse Group | |
| 16.01.20 | AstraZeneca Outperform | Credit Suisse Group | |
| 16.01.20 | Nokia Equal weight | Barclays Capital | |
| 16.01.20 | Ericsson (Telefon L.M.Ericsson) (B) overweight | Barclays Capital | |
| 14.01.20 | Nokia Equal-Weight | Morgan Stanley | |
| 14.01.20 | ABB (Asea Brown Boveri) Underweight | JP Morgan Chase & Co. | |
| 13.01.20 | Ericsson (Telefon L.M.Ericsson) (B) Conviction Buy List | Goldman Sachs Group Inc. | |
| 10.01.20 | ABB (Asea Brown Boveri) Underweight | JP Morgan Chase & Co. | |
| 09.01.20 | Volvo (B) Sell | UBS AG | |
| 06.01.20 | Novo Nordisk neutral | Morgan Stanley | |
| 06.01.20 | AstraZeneca neutral | Morgan Stanley | |
| 06.01.20 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 06.01.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 06.01.20 | Volvo (B) Neutral | JP Morgan Chase & Co. | |
| 06.01.20 | Novo Nordisk kaufen | Bernstein Research | |
| 02.01.20 | ABB (Asea Brown Boveri) Underweight | JP Morgan Chase & Co. | |
| 20.12.19 | A.P. Moeller - Maersk A-S (B) buy | Jefferies & Company Inc. | |
| 19.12.19 | Volvo (B) buy | Kepler Cheuvreux | |
| 19.12.19 | A.P. Moeller - Maersk A-S (B) Neutral | Goldman Sachs Group Inc. | |
| 18.12.19 | Volvo (B) buy | Goldman Sachs Group Inc. | |
| 17.12.19 | AstraZeneca Outperform | Credit Suisse Group | |
| 17.12.19 | Novo Nordisk Underperform | Jefferies & Company Inc. |
